Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.
作者信息
Sinha Neelam, Sinha Sanju, Cheng Kuoyuan, Madan Sanna, Erez Ayelet, Ryan Bríd M, Schäffer Alejandro A, Aldape Kenneth, Ruppin Eytan
机构信息
Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD.
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
出版信息
JCO Precis Oncol. 2021 Nov;5:1147-1150. doi: 10.1200/PO.21.00168.
Abstract
摘要
相似文献
1
Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.使用最近获批的肿瘤突变负荷生物标志物对患者进行免疫治疗分层可能会引入性别偏差。
JCO Precis Oncol. 2021 Nov;5:1147-1150. doi: 10.1200/PO.21.00168.
2
Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.肿瘤突变负担作为免疫治疗反应的生物标志物：肿瘤免疫学中的免疫组学方法。
Curr Mol Med. 2024;24(12):1461-1469. doi: 10.2174/0115665240266906231024111920.
3
The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy.在癌症免疫疗法的患者选择中，癌症类型、panel 大小和肿瘤突变负担阈值之间的相互作用。
PLoS Comput Biol. 2020 Nov 9;16(11):e1008332. doi: 10.1371/journal.pcbi.1008332. eCollection 2020 Nov.
4
Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.热点还是冷门：肿瘤突变负荷 (TMB) 作为泌尿生殖系统癌症免疫治疗反应的生物标志物。
Urology. 2021 Jan;147:119-126. doi: 10.1016/j.urology.2020.10.030. Epub 2020 Nov 1.
5
Predicting immunotherapy response through genomics.通过基因组学预测免疫疗法反应。
Curr Opin Genet Dev. 2021 Feb;66:1-9. doi: 10.1016/j.gde.2020.11.004. Epub 2020 Dec 8.
6
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.基于免疫检查点抑制剂的癌症免疫治疗耐药性：靶点、生物标志物和治疗方法。
Drug Resist Updat. 2020 Dec;53:100718. doi: 10.1016/j.drup.2020.100718. Epub 2020 Jul 15.
7
The value of tumor mutational burden to select patients for immunotherapy.肿瘤突变负荷在选择免疫治疗患者中的价值。
Expert Rev Anticancer Ther. 2021 Jan;21(1):1-3. doi: 10.1080/14737140.2020.1831386. Epub 2020 Oct 10.
8
Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.肿瘤突变负担预测免疫检查点抑制剂在结直肠癌中的疗效：系统评价和荟萃分析。
Front Immunol. 2021 Sep 29;12:751407. doi: 10.3389/fimmu.2021.751407. eCollection 2021.
9
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.改善多种癌症类型的免疫检查点阻断疗效预测。
Nat Biotechnol. 2022 Apr;40(4):499-506. doi: 10.1038/s41587-021-01070-8. Epub 2021 Nov 1.
10
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.程序性死亡配体1（PD-L1）是抗程序性死亡蛋白1（PD-1）治疗的一致性生物标志物吗？Balstilimab在病毒驱动肿瘤中的模型。
Oncogene. 2021 Feb;40(8):1393-1395. doi: 10.1038/s41388-020-01611-6. Epub 2021 Jan 26.
引用本文的文献
1
The role of the sex hormone-gut microbiome axis in tumor immunotherapy.性激素-肠道微生物群轴在肿瘤免疫治疗中的作用。
Gut Microbes. 2023 Jan-Dec;15(1):2185035. doi: 10.1080/19490976.2023.2185035.
2
Genetic and Clinical Characteristics of Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival.突变型黑色素瘤的遗传和临床特征显示肿瘤突变负荷高，但对患者生存无影响。
Cancers (Basel). 2022 Apr 22;14(9):2090. doi: 10.3390/cancers14092090.
3
Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma.晚期黑色素瘤年轻患者对抗程序性死亡蛋白1（PD1）免疫疗法无反应的潜在原因
Life (Basel). 2021 Nov 30;11(12):1318. doi: 10.3390/life11121318.
本文引用的文献
1
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.肿瘤和 T 细胞内在机制对检查点抑制敏感性的荟萃分析。
Cell. 2021 Feb 4;184(3):596-614.e14. doi: 10.1016/j.cell.2021.01.002. Epub 2021 Jan 27.
2
The association between tumor mutational burden and prognosis is dependent on treatment context.肿瘤突变负担与预后的关联取决于治疗背景。
Nat Genet. 2021 Jan;53(1):11-15. doi: 10.1038/s41588-020-00752-4. Epub 2021 Jan 4.
3
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.肿瘤突变负荷作为免疫治疗生物标志物面临的挑战。
Cancer Cell. 2021 Feb 8;39(2):154-173. doi: 10.1016/j.ccell.2020.10.001. Epub 2020 Oct 29.
4
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
5
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study.帕博利珠单抗在错配修复蛋白表达部分或完全缺失的复发性高级别胶质瘤中的活性：一项单中心、观察性前瞻性试点研究。
Cancers (Basel). 2020 Aug 14;12(8):2283. doi: 10.3390/cancers12082283.
6
Strength of immune selection in tumors varies with sex and age.肿瘤中的免疫选择强度随性别和年龄而异。
Nat Commun. 2020 Aug 17;11(1):4128. doi: 10.1038/s41467-020-17981-0.
7
The impact of sex and gender on immunotherapy outcomes.性别对免疫治疗结果的影响。
Biol Sex Differ. 2020 May 4;11(1):24. doi: 10.1186/s13293-020-00301-y.
8
Sex-associated molecular differences for cancer immunotherapy.癌症免疫治疗的性别相关分子差异。
Nat Commun. 2020 Apr 14;11(1):1779. doi: 10.1038/s41467-020-15679-x.
9
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.对转移性黑色素瘤患者接受 PD1 阻断治疗的临床结局进行综合分子和临床建模。
Nat Med. 2019 Dec;25(12):1916-1927. doi: 10.1038/s41591-019-0654-5. Epub 2019 Dec 2.
10
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.抗 PD-1 免疫疗法治疗胶质母细胞瘤的免疫和基因组相关性。
Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11.
Zotero 插件